Literature DB >> 15506033

Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus.

S Svenmarker1, M Appelblad, E Jansson, S Häggmark.   

Abstract

BACKGROUND: Measurement of the activated clotting time (ACT) represents a standard method for coagulatory assessments. The test employs specific agents to trigger the coagulation process. The present study aimed to compare kaolin (Hemotec) versus a combination of silica, kaolin and phospholipid (Hemochron Jr) ACTs.
METHODS: Hemotec and Hemochron Jr ACT monitors were compared by simultaneous measurement of paired arterial blood samples (n = 114) with respect to precision and bias during clinical conditions of cardiopulmonary bypass (CPB). The influence of haemodilution on the ACT was tested in an ex-vivo model.
RESULTS: The precision of Hemotec and Hemochron Jr ACT measurements attained 21 +/- 2.6 s versus 27.0 +/- 2.6 s (p = 0.126) during CPB and 2.5 +/- 2.2 s versus 9.4 +/- 6.9 s (p = 0.000) after protamine administration, respectively. The Hemochron Jr monitor was associated with a bias of -102 +/- 13.7 s compared to the Hemotec ACT monitor (p = 0.000) during CPB and -6.9 +/- 2.9 s after protamine (p = 0.025). Linear regression analysis of ACT readings between monitors reached r = 0.526 (p = 0.000). Hemochron Jr ACT values correlated with the erythrocyte volume fraction r = 0.379 (p = 0.000). Ex-vivo data indicated that the Hemotec ACT monitor was associated with relatively higher ACT readings after haemodilution.
CONCLUSION: The ACT is not a standardized measure. Test results are strongly associated with the specific compounds used to initiate the coagulation process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15506033     DOI: 10.1191/0267659104pf755oa

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  5 in total

1.  Report from AmSECT's International Consortium for Evidence- Based Perfusion Consensus Statement: Minimal Criteria for Reporting Cardiopulmonary Bypass-Related Contributions to Red Blood Cell Transfusions Associated With Adult Cardiac Surgery.

Authors:  Donald S Likosky; Robert A Baker; Timothy A Dickinson; Daniel J FitzGerald; M Filip De Somer; Robert C Groom; David FitzGerald; Kenneth G Shann; Michael Poullis; Bruce D Spiess; Karim Jabr; Mark T Lucas; James D Ferguson; Shahna L Bronson
Journal:  J Extra Corpor Technol       Date:  2015-06

2.  Evaluations of activated clotting time technologies require understanding activating clotting time system differences.

Authors:  Marcia L Zucker
Journal:  J Extra Corpor Technol       Date:  2013-03

Review 3.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.

Authors:  Colleen E Gruenwald; Cedric Manlhiot; Lynn Crawford-Lean; Celeste Foreman; Leonardo R Brandão; Brian W McCrindle; Helen Holtby; Ross Richards; Helen Moriarty; Glen Van Arsdell; Anthony K Chan
Journal:  J Extra Corpor Technol       Date:  2010-03

4.  Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation? A Clinical Evaluation of Two ACT Monitors.

Authors:  Samuel Nilsson; Micael Appelblad; Staffan Svenmarker
Journal:  J Extra Corpor Technol       Date:  2020-09

5.  Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.

Authors:  Jung Min Lee; Eun Young Park; Kyung Mi Kim; Jong Chan Won; Tack Koon Jung; Soo Kyung Lee
Journal:  J Int Med Res       Date:  2017-10-04       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.